FDA approves IND application for Ph 1 trial of KGX105 monotherapy in locally advanced or metastatic solid tumors
Dr. Weidong Jiang, Chief Executive Officer of KangaBio, commented: “The FDA’s clearance of KGX105, our second pipeline candidate, for clinical trials marks a pivotal moment in the company’s growth and reflects the increasing maturity of our prodrug platform technology. We look forward to thoroughly evaluating the safety and preliminary efficacy of KGX105 in this Phase 1 study, which will lay a solid foundation for its continued clinical development. The encouraging early clinical results from KGX101 have further validated our prodrug platform, offering valuable insights and confidence as we advance our pipeline. We extend our sincere gratitude to both existing and new investors for their continued trust and support. We are committed to accelerating the progress of our clinical programs and bringing new treatment hope to cancer patients around the world.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo